ZGZofia Gorzoch-Burduk

Zofia Gorzoch-Burduk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zofia Gorzoch-Burduk has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Impact of Embolization on Surgical Conditions and Treatment Outcomes in Carotid Body Tumors: A Multicenter Observational Study

    by Jakub Burduk, Zofia Gorzoch-Burduk, Paweł Witkowski, Bogusław Mikaszewski, Paulina Mierzwińska-Dolny, Paweł Burduk, Jakub Robak, Katarzyna Malec

    Introduction: Carotid body tumors are rare neoplasms originating from paraganglionic cells, located near the bifurcation of the common carotid artery. These lesions are usually benign and asymptomatic, but when carotid body tumors increase in size they may begin to cause symptoms. Carotid body paragangliomas are treated surgically, with preoperative embolization performed in some cases. There is ongoing debate as to whether preoperative embolization provides benefits for patients.Aim: The aim of the study was to evaluate the influence of preoperative carotid body paraganglioma embolization on surgical safety, operative time, and overall treatment outcome.Materials and methods: A cohort of 36 patients (26 women, 10 men) with a mean age of 51 years, treated at three clinical centers over the past 15 years, was included. Operative times, lengths of hospital stay, postoperative complications, perioperative blood loss, and treatment outcomes were compared. Additionally, demographic and clinical data were collected from medical history and physical examination.Conclusions: Preoperative embolization offers benefits compared with surgery alone, including fewer complications and a shorter mean operative time. The mean length of hospital stay was comparable between the two groups. No reduction in blood loss was observed among patients who underwent embolization prior to surgery.

  • Open Access

    GROWING ROLE OF ROBOTIC-ASSISTED SURGERY IN ADULT PATIENTS - A COMPREHENSIVE REVIEW

    by Anna Kocik, Ilona Tadulewicz, Natalia Nowak, Mateusz Drozd, Aleksandra Kozłowska, Zuzanna Butkowska, Łucja Komisarczyk, Tadeusz Kornela, Aleksandra Góralska, Zofia Gorzoch-Burduk

    Introduction: Robotic-Assisted Surgery (RAS) has transitioned from a technological curiosity to a foundation of modern surgery in the last few years. This review aims to evaluate the current status, clinical outcomes, economic implications, and expanding indications of RAS in adult patients across urologic, gynecologic, colorectal, and general surgical disciplines. Methods: A review of the literature was conducted using PubMed, Scopus, and Web of Science databases for English-language articles published up to 2025. The analysis focused on randomized controlled trials (RCTs), systematic reviews, and large-cohort meta-analyses comparing RAS with open surgery and conventional laparoscopy. Results: The analysis indicates that RAS offers superior visualization and improved ergonomics compared to conventional laparoscopy. In urology, RAS has become the gold standard for prostatectomy, showing statistically significant reductions in estimated blood loss (EBL) and improved functional recovery (continence and potency). In gynecology and general surgery, RAS demonstrates lower conversion rates to open surgery, particularly in obese cohorts and deep pelvic dissections. While operative times are frequently longer during the learning curve, total length of hospital stay is consistently reduced. Conclusions: Robotic surgery has proven advantageous in minimizing patient trauma and assisting with complex cases where conventional laparoscopy struggles. The primary barrier remains the high upfront cost; however, these expenses may be offset over time by reduced length of stay and lower complication rates, strengthening the economic case for RAS.

  • Open Access

    MODERN BIOLOGICAL TREATMENT METHODS FOR ALOPECIA AREATA: A COMPREHENSIVE REVIEW

    by Ilona Tadulewicz, Natalia Nowak, Mateusz Drozd, Aleksandra Kozłowska, Zuzanna Butkowska, Anna Kocik, Łucja Komisarczyk, Tadeusz Kornela, Aleksandra Góralska, Zofia Gorzoch-Burduk

    Introduction: Alopecia areata (AA) is a chronic, immune-mediated hair-loss disorder driven by cytotoxic T-cell activation and loss of hair-follicle immune privilege. Janus kinase (JAK) inhibitors and emerging targeted biologics have reshaped treatment options for moderate-to-severe AA. This review compared three approved JAK-based therapies (ritlecitinib, baricitinib, deuruxolitinib) and summarized evidence on investigational biologic agents. Materials and Methods: This narrative review was based on a structured search of PubMed and Google Scholar for English-language publications available up to 2025. Search terms included “alopecia areata,” “biologic therapy,” “JAK inhibitors,” “ritlecitinib,” “baricitinib,” “deuruxolitinib,” and “immunomodulation.” Phase 2 and 3 trials, early-phase studies, observational research, and review articles were screened. Full texts were assessed to extract information on mechanisms of action, JAK-isoform selectivity, clinical efficacy measured by SALT outcomes, safety, and emerging therapeutic strategies. Results: All three JAK inhibitors showed significant efficacy compared with placebo but differed in selectivity and response dynamics. Ritlecitinib (JAK3/TEC) demonstrated a rapid onset of action and a favorable safety profile. Baricitinib (JAK1/2) produced gradual, sustained improvement supported by extensive long-term data. Deuruxolitinib (JAK1/2/TYK2) achieved high SALT ≤20 response rates across THRIVE-AA trials. Emerging biologics such as bempikibart (anti–IL-7Rα) and early investigational agents (ALD-102, DR-01) showed preliminary efficacy, though evidence remains limited by short follow-up and lack of predictive biomarkers. Conclusions: JAK inhibitors constitute a major therapeutic advance for moderate-to-severe AA, providing meaningful clinical benefit with acceptable safety. Novel biologic agents may offer more selective and durable immune modulation. Long-term studies and development of precision-medicine approaches will be essential to optimize future AA management.

  • Open Access

    A Review of Candida auris

    by Marta Krzyzaniak, Izabela Brynczka, Klaudia Martyna Patrzykąt, Zofia Gorzoch- Burduk, Julia Puzio, Paula Marcinkowska, Michał Jezierski, Kinga Popielarska, Ewelina Nowicka, Kamila Wróblewska

    Background. Candida auris is an emerging, multidrug-resistant fungal pathogen ofsignificant public health concern. Noted for its environmental persistence and hightransmissibility, it poses a substantial threat in healthcare settings, particularly inintensive care units, driving the need for specific infection control protocols. Aim. The aim of this study was a comparative analysis of environmental disinfectionmethods used in the prevention and control of Candida auris in various countries andhealthcare facilities.Material and methods. This review analyzed literature from 2016-2025, sourcedfrom databases such as PubMed, alongside public health guidelines andepidemiological reports. A comparative analysis of the selected data wasconducted. Results. Disinfection strategies against C. auris primarily recommend chlorine- andhydrogen peroxide-based agents, with UV-C and vaporized hydrogen peroxide (VHP)noted as supplementary measures. A comparative analysis revealed significantinternational divergence, particularly regarding quaternary ammonium compounds(QACs), which are largely restricted except in specific contexts like India. Overallefficacy is highly variable and dependent on disinfectant selection, workflow, stafftraining, and the consistency of protocol implementation. Conclusions. Chlorine- and peroxide-based disinfectants are most effective against C.auris, while QACs are discouraged despite their localized use. To counter variabilityin international guidelines, a unified regulatory framework is recommended. Keyrecommendations include standardizing procedures, enhancing staff training, andmaintaining strict surveillance. Further research, including hospital case studies, isneeded due to insufficient current data.

  • Open Access

    A Review of Candida auris

    by Marta Krzyzaniak, Izabela Brynczka, Klaudia Martyna Patrzykąt, Zofia Gorzoch- Burduk, Julia Puzio, Paula Marcinkowska, Michał Jezierski, Kinga Popielarska, Ewelina Nowicka, Kamila Wróblewska

    Background. Candida auris is an emerging, multidrug-resistant fungal pathogen ofsignificant public health concern. Noted for its environmental persistence and hightransmissibility, it poses a substantial threat in healthcare settings, particularly inintensive care units, driving the need for specific infection control protocols. Aim. The aim of this study was a comparative analysis of environmental disinfectionmethods used in the prevention and control of Candida auris in various countries andhealthcare facilities.Material and methods. This review analyzed literature from 2016-2025, sourcedfrom databases such as PubMed, alongside public health guidelines andepidemiological reports. A comparative analysis of the selected data wasconducted. Results. Disinfection strategies against C. auris primarily recommend chlorine- andhydrogen peroxide-based agents, with UV-C and vaporized hydrogen peroxide (VHP)noted as supplementary measures. A comparative analysis revealed significantinternational divergence, particularly regarding quaternary ammonium compounds(QACs), which are largely restricted except in specific contexts like India. Overallefficacy is highly variable and dependent on disinfectant selection, workflow, stafftraining, and the consistency of protocol implementation. Conclusions. Chlorine- and peroxide-based disinfectants are most effective against C.auris, while QACs are discouraged despite their localized use. To counter variabilityin international guidelines, a unified regulatory framework is recommended. Keyrecommendations include standardizing procedures, enhancing staff training, andmaintaining strict surveillance. Further research, including hospital case studies, isneeded due to insufficient current data.

  • Open Access

    The Impact of Long-Term Running on the Development of Osteoarthritis: A Literature Review

    by Zofia Gorzoch-Burduk, Ewelina Nowicka, Izabela Brynczka, Klaudia Martyna Patrzykąt, Julia Puzio, Paula Marcinkowska, Marta Krzyżaniak, Michał Jezierski, Kinga Popielarska, Kamila Wróblewska

    Background: Osteoarthritis is a common condition that exerts a substantial impact on patients’ quality of life. It is associated with chronic joint pain, stiffness, and functional limitations. The prevalence of osteoarthritis continues to increase due to its strong association with aging and obesity. Running is a popular form of physical activity that provides numerous well-established health benefits. Determining its relationship with osteoarthritis is therefore of great importance. Aim: The aim of this study was to determine how long-term running, currently one of the most popular sports, influences the development of osteoarthritis of the lower-limb joints. Material and Methods: A literature review of publications from recent years was conducted to identify and summarize the most relevant findings and reports on this topic. Results: The findings were inconclusive. Recreational running, according to most sources, appears to be neutral or beneficial for joint health. Physicians should recommend this form of activity due to its substantial health advantages across numerous domains. However, high-level competitive, elite, and olympic running has been associated with an increased risk of developing osteoarthritis. Conclusions: High-intensity running that may lead to injuries contributing to the development of osteoarthritis should be avoided, but recreational running should not be given up.

  • Open Access

    Metformin in Breast Cancer: Molecular Mechanisms, Preclinical Evidence and Clinical Implications

    by Ewelina Nowicka, Izabela Brynczka, Klaudia Martyna Patrzykąt, Zofia Gorzoch-Burduk, Julia Puzio, Paula Marcinkowska, Marta Krzyżaniak, Michał Jezierski, Kinga Popielarska, Kamila Wróblewska

    Background: Metformin, a first-line therapy for type 2 diabetes mellitus, has recently attracted attention for its potential anticancer properties. Preclinical and clinical evidence suggests that it modulates cancer cell metabolism, proliferation and survival pathways, indicating its possible role as an adjunct therapeutic agent, particularly in breast cancer. Aim: To summarize current knowledge on the mechanisms of action, preclinical outcomes and clinical implications of metformin use in breast cancer. Material and methods: A comprehensive literature search was conducted in PubMed, Scopus, Web of Science and Google Scholar databases, including publications up to 2025. Eligible sources encompassed preclinical studies, clinical trials, observational data, meta-analyses and reviews addressing metformin in breast cancer. Results: Metformin demonstrates multifaceted antitumor activity, including inhibition of cell proliferation, reduced angiogenesis, downregulation of the PI3K/AKT/mTOR pathway, depletion of cancer stem cell populations and improved chemotherapy response. Clinical benefits are most evident in patients with type 2 diabetes and HER2-positive tumors, although findings in the general population remain inconsistent. Conclusions: Metformin appears to be a promising supportive therapy in selected breast cancer subgroups, particularly in metabolically burdened patients. Further high-quality randomized trials are essential to clarify its clinical relevance and identify biomarkers predicting treatment response.

  • Open Access

    Xylitol, erythritol as sucrose replacements: their effect on oral health - narrative review

    by Julia Puzio, Izabela Brynczka, Zofia Gorzoch-Burduk, Michał Jezierski, Marta Krzyżaniak, Ewelina Nowicka, Paula Marcinkowska, Kinga Popielarska, Klaudia Martyna Patrzykąt, Kamila Wróblewska

    Background:Dental caries in one of the most common chronic diseases worldwide. Sucrose consumption is one of the main cause of dental caries due to biofilm acidification, microbial dysbiosis, and demineralization.Researchers have centered their attention on developing sucrose substitutes with special emphasis on polyols, which can reduce cariogenicity. Aim: This narrative review aims to integrate existing evidence with regard to the mechanism of action, clinical efficacy, and safety usage of xylitol, erythritol, in relation to preventing dental caries, maintaining periodontal and overall oral health. Methods: This narrative review was conducted through structured research of PubMed (2015-2025).Recent clinical trials, in vitro studies, systematic reviews were included. Results: Xylitol demonstrates consistent inhibition effects on S.mutans, reduced biofilm adhesive properties, lowered acid production leading to a gradual change in cariogenic oral microbiome. Erythritol is found with similar or better activity levels in most studies. Unlike sucrose, polyols lack the fermentable activity, preventing a lowered pH and subsequent enamel demineralization. Conclusions:Sucrose substitutes have emerged as potential efficacious and biologically credible additions to established prophylactic modalities. Their abilities, makes theme promising additions to caries prophylaxis and initial periodontal therapy itself. There is a need for further well-designed clinical studies to establish a precise dosage and efficacy of these substances.

  • Open Access

    Taurine in Sports: Impact on Athletic Performance, Muscle Recovery and Neurological Function in Athletes – A Narrative Review

    by Michał Jezierski, Izabela Brynczka, Klaudia Martyna Patrzykąt, Zofia Gorzoch-Burduk, Julia Puzio, Paula Marcinkowska, Marta Krzyżaniak, Kinga Popielarska, Ewelina Nowicka, Kamila Wróblewska

    Purpose: This review examines the ergogenic potential of taurine in athletes, focusing on its effects on aerobic and anaerobic performance, exercise-induced muscle damage (EIMD), recovery, and neurological aspects such as pain perception and cognitive focus. It also considers how dose, timing, and duration (acute vs. chronic use) influence outcomes.Materials and Methods: A narrative review of 19 peer-reviewed studies (RCTs, meta-analyses, observational research) from PubMed, Scopus, and Google Scholar was conducted. Studies involved swimming, running, cycling, speed skating, and resistance training. Taurine doses ranged from 0.05–6 g/day. Outcomes included VO2max, time to exhaustion, time-trial performance, anaerobic power (Wingate, vertical jump), biomarkers of muscle damage (CK, LDH), oxidative stress (MDA, SOD, GSH), pain, and RPE.Results: Effects varied by exercise type and dosing. In anaerobic tasks, acute taurine (6 g) enhanced peak and mean power and lowered RPE in elite athletes, while broader data indicate improved vertical jump. Endurance results were inconsistent: some studies showed no changes in VO2max or time-trial performance, whereas others reported increased time to exhaustion and greater lipid use. Taurine consistently reduced CK, LDH, and MDA after exercise, especially 24–48 hours post-effort. It also affected pain perception up to 96 hours and showed neuroprotective properties in animal models.Conclusions: Taurine is a safe option for reducing EIMD and oxidative stress, supporting recovery. Ergogenic benefits appear stronger in anaerobic, high-power activities than in endurance sports, where outcomes are mixed and may relate to non-responder effects in elite athletes. Taurine’s influence on lipid metabolism and lactate kinetics suggests support for anaerobic energy processes. Further research should refine dosing strategies and explore neuroprotective roles in contact sports.


  • Open Access

    Old Drugs, New Roles: Non-Cardiac Uses of Beta-Blockers – An Updated Systematic Review

    by Izabela Brynczka, Michał Jezierski, Ewelina Nowicka, Klaudia Martyna Patrzykąt, Zofia Gorzoch-Burduk, Julia Puzio, Paula Marcinkowska, Marta Krzyżaniak, Kinga Popielarska, Kamila Wróblewska

    Background: β-adrenergic blockers have long been used in cardiovascular medicine, yet growing evidence shows therapeutic potential beyond cardiac disease. Their pleiotropic effects—ranging from modulation of sympathetic signaling to anti-angiogenic and immunomodulatory actions—have increased interest in non-cardiac applications and drug repurposing.Aim: To review non-cardiac roles of β-blockers, summarize recent findings (2020–2025), compare mechanisms across indications, and highlight emerging oncologic and immunomodulatory uses.Material and Methods: This narrative review was based on PubMed, Google Scholar and Scopus searches (2020–2025) using terms including “beta-blockers”, “propranolol”, “timolol”, “repurposing”, “glaucoma”, “hemangioma” and “oncology”. Randomized trials, cohort studies, translational basic research and meta-analyses were included; studies without relevance to non-cardiac mechanisms or lacking extractable data were excluded.Results: Non-selective β-blockers remain essential in portal hypertension, reducing portal pressure and preventing bleeding. In infantile hemangioma, oral propranolol is more effective than topical timolol, with early initiation predicting better outcomes. Propranolol, timolol and metoprolol are effective in migraine prophylaxis, while propranolol remains first-line therapy for essential tremor. Timolol is a cornerstone glaucoma treatment, lowering intraocular pressure and delaying progression from ocular hypertension. In oncology, propranolol shows preclinical activity against proliferation, angiogenesis and immunosuppression, though clinical evidence is inconsistent.Conclusions: β-blockers represent a versatile drug class with established non-cardiac indications and promising emerging applications, especially in oncology. Their safety and broad mechanistic profile support further repurposing, but high-quality prospective trials remain necessary.